CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.

  title={CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.},
  author={Navid Redjal and Jennifer A W Chan and Rosalind A. Segal and Andrew L Kung},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={12 22},
PURPOSE The chemokine receptor CXCR4 is expressed in many different cancers. In malignant brain tumors, CXCR4 signaling has been implicated in tumor growth, survival, and migration, and pharmacologic inhibition of CXCR4 results in decreased tumor growth in preclinical models. To understand how CXCR4 inhibitors may be incorporated into clinical therapy, we examined determinants of responsiveness to CXCR4 inhibition. Because optimal use of CXCR4 inhibition will likely be a part of multimodality… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 63 extracted citations


Publications referenced by this paper.
Showing 1-5 of 5 references

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

Proceedings of the National Academy of Sciences of the United States of America • 2003
View 5 Excerpts

Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro

S Barbero, BajettoA, R Bonavia
AnnNYAcad Sci 2002;973:60^9 • 2002

Similar Papers

Loading similar papers…